ACETO Corp (ACET) Closes $100M PACK Pharma Acquisition

ACETO Corp (Nasdaq: ACET) announced that its wholly-owned subsidiary, Rising Pharmaceuticals ("RISING"), has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, LLC ("PACK"), a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products. The total transaction value is approximately $100 million.

At closing, ACETO paid $80 million in cash, adjusted for working capital, and $5 million in ACETO stock. The definitive purchase agreement also provides for potential additional payments totaling no more than $15 million, based on the achievement of certain performance-based targets. The Company is also assuming certain of PACK's obligations incurred in the normal course of business, subject to the terms and conditions of the purchase agreement. PACK recorded net sales of approximately $46 million for calendar year 2013. Based upon the consideration paid at closing, including receipt of working capital, this transaction represents a multiple of calendar 2013 EBITDA of 8.8 on a pro forma basis, adjusted to include expected cost savings. Management expects the transaction, including deal-related expenses, to be approximately $0.08 per share dilutive to fiscal 2014 earnings, slightly accretive to the fiscal 2015 earnings, beginning in the second quarter, and increasingly accretive in years thereafter.

"The strategically important and complementary business combination of PACK with our Rising Pharmaceutical business further increases the mix of higher margin finished dosage generic pharmaceuticals in ACETO's revenue base and doubles the size of our development pipeline of new generic products," said Sal Guccione, Chief Executive Officer of ACETO. "In addition, the acquisition establishes ACETO in branded generics for the first time. We welcome the management and employees of PACK Pharmaceuticals to ACETO and look forward to building significant shareholder value together."

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Paramount Global (PARA) and Skydance are closer to a merger - CNBC